MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, G. K.
Right arrow Articles by Sikic, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, G. K.
Right arrow Articles by Sikic, B. I.

Vol. 57, Issue 4, 769-777, April 2000

Loss of Cyclosporin and Azidopine Binding Are Associated with Altered ATPase Activity by a Mutant P-glycoprotein with Deleted Phe335

G. Kevin Chen, Norman J. Lacayo, George E. Durán, Dalia Cohen, and Branimir I. Sikic

Oncology Division, Department of Medicine, and the Cancer Biology Program, Stanford University School of Medicine, Stanford, California (G.K.C., N.J.L., G.E.D., B.I.S.); and Oncology Research Group, Novartis Pharmaceutical Corporation, East Hanover, New Jersey (D.C.)

In this study, we further characterize a mutant P-glycoprotein (P-gp) that has a deletion of Phe335 and is resistant to inhibition by cyclosporins. Photoaffinity labeling with [3H]cyclosporine and [3H]azidopine revealed markedly decreased binding to the mutant P-gp compared with wild-type P-gp. Expression of the mutant P-gp in multidrug-resistant variant cell line MES-SA/DxP (DxP) cells was associated with a 2-fold higher basal ATPase activity relative to multidrug-resistant cell line MES-SA/Dx5 (Dx5) cells with wild-type P-gp. Cyclosporine inhibited ATPase activity in both cell types, whereas the cyclosporin D analog valspodar (PSC 833), vinblastine, and dactinomycin stimulated ATPase activity in Dx5 but not in mutant DxP cells. Moreover, the cell lines differed in their responses to verapamil, which produced greater stimulation of ATPase in Dx5 than DxP cells. Verapamil significantly reversed the [3H]daunorubicin accumulation defect in wild-type Dx5 cells, but it had no significant effect on [3H]daunorubicin accumulation in the mutant DxP cells. Verapamil was not transported by cells expressing either mutant or wild-type P-gp. Vanadate trapping of azido-ATP was markedly impaired in mutant P-gp. In conclusion, our data demonstrate that Phe335 of transmembrane 6 is an important amino acid residue for the formation of cyclosporine and azidopine drug-binding site(s). Phe335 also plays a role in the coupling of verapamil binding and modulation of daunorubicin intracellular accumulation in wild-type P-gp. In addition, Phe335 in transmembrane 6 may play a role in coupling drug binding to ATPase activity. The deletion of Phe335 results in a significant increase in the basal ATPase activity with a concomitant decrease in its ability to trap ATP and transport some P-gp substrates.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
K. F. K. Ejendal and C. A. Hrycyna
Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A
Mol. Pharmacol., March 1, 2005; 67(3): 902 - 911.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
D. J. Gruol, J. Bernd, A. E. Phippard, I. Ojima, and R. J. Bernacki
The Use of a Novel Taxane-Based P-Glycoprotein Inhibitor to Identify Mutations That Alter the Interaction of the Protein with Paclitaxel
Mol. Pharmacol., July 1, 2001; 60(1): 104 - 113.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics